使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and Gentlemen. Good morning and welcome to the Apyx Medical Third Quarter, 2024 earnings conference call at this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from LifeSci advisors. Please go ahead.
各位女士、先生。早安,歡迎參加 Apyx Medical 2024 年第三季財報電話會議;此刻所有與會者皆處於僅收聽模式。正式簡報結束後將進行簡短的問答環節。若在會議期間需要接線員協助,請在電話鍵盤按下星號再按 0。提醒各位,本次會議將被錄音。現在很榮幸為各位介紹主持人:來自 LifeSci Advisors 的 Jeremy Feffer。請開始。
Jeremy Feffer
Jeremy Feffer
Thank you and welcome everyone to our third quarter. 2024 earnings call representing the company on the call are Stavros Vizirgianakis, executive Chairman of the Apyx Board of Directors will participate in the first part of the call, Charlie Goodwin, Chief Executive Officer and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated including that limitation that was identified in the risk factors section of our most recent annual report on form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, this call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures, reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website. I would now like to turn the call over to Mr Charles Goodwin, Apyx Medical's President and Chief Executive Officer, please go ahead.
謝謝,並歡迎各位參加我們 2024 年第三季財報電話會議。代表公司出席本次電話會議的有:Apyx 董事會執行董事長 Stavros Vizirgianakis(將參與會議前半段)、執行長 Charlie Goodwin,以及 Apyx 財務長 Matt Hill。在開始之前,我想提醒各位,我們今天的發言以及對各位提問的回應可能包含前瞻性陳述;該等陳述係基於管理層目前的預期,並涉及固有風險與不確定性,可能導致實際結果與所示內容存在重大差異,包括但不限於我們最近一期 Form 10-K 年報、最近一期 10-Q 季報,以及公司向美國證券交易委員會(SEC)提交之其他文件中「風險因素」章節所識別的限制。相關因素可能會不時於我們向 SEC 提交的文件中更新,並可於我們網站查閱。我們不承擔因新資訊、未來事件或其他原因而公開更新或修訂任何前瞻性陳述之義務;此外,本次電話會議亦將提及若干未依一般公認會計原則(GAAP)計算之財務衡量指標。我們通常將其稱為非 GAAP 財務衡量指標;該等非 GAAP 財務衡量指標與依 GAAP 計算並呈列之最可比衡量指標之調節表,可於我們網站投資人關係專區的財報新聞稿中取得。現在我想把電話交給 Apyx Medical 總裁兼執行長 Charles Goodwin 先生,請開始。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Thank you Jeremy and thank you all for joining us today for our usual format on these quarterly calls. I will be providing a review of our performance in the third quarter and then I will turn the call over to Matt for a review of our third quarter financial results and full year guidance. We will then open up the call for your questions. However, before I get started, I would like to have Stavros take a few minutes to address the strategic changes announced this morning at the board and corporate levels of Apyx as well as actions taken to strengthen the company's balance sheet, Stavros.
謝謝你,Jeremy,也謝謝各位今天加入我們,延續我們這些季度電話會議一貫的流程。我將先回顧我們第三季的營運表現,接著把電話交給 Matt,請他回顧第三季財務結果以及全年財測指引。之後我們將開放各位提問。不過在我開始之前,我想先請 Stavros 花幾分鐘說明今天早上宣布的 Apyx 董事會與公司層級的策略性變更,以及為強化公司資產負債表所採取的行動。Stavros。
Stavros Vizirgianakis - Executive Chairman of the Board of Directors
Stavros Vizirgianakis - Executive Chairman of the Board of Directors
Thank you Charlie for having me join you on today's call to address the strategic changes happening at Apyx along with the financial actions taken which we believe strengthen the company's balance sheet. First as announced in the press release issued earlier today, the Apyx board of directors and management team have decided to implement an organizational restructuring that is expected to better focus the company's resources and streamline operations. Under the restructuring, Apyx reduced its US workforce by nearly 25%. As part of the reduction Todd Hornsby the executive Vice President of sales and marketing will be leaving the company effective immediately. Todd has been a valuable member of our sales team for more than 10 years. We are grateful for his contributions to the company during this time. Under the new structure, Charlie has assumed direct responsibility for the sales organization in addition to his other duties as CEO as a reminder, Charlie has decades of experience leading medical device sales teams and is well positioned to support the function in order to free up Charlie's time. I'm also pleased to announce Sean Roman has been promoted from his current position of Vice President, research and development to Chief Operating Officer, Sean has been with the company since 2015 and is well qualified for his new role in a moment. Matt will discuss the specifics in regards to the expected cost reductions and onetime costs as well as how the restructuring is expected to extend our runway into 2027. I wanted to be clear that this wasn't a decision the board of management took lightly. We carefully evaluated our options and determined that this restructuring was needed to right size the business looking to the future with the introduction of our game changing new platform which will enable the company to dominate surgical aesthetics with various best in class solutions. We expect to see an even greater utilization of our movie on technology and a return to overall growth. Charlie will elaborate on this exciting new platform momentarily turning to the board changes being implemented. We have decided to right size the board reducing the number of seats to five directors from the current eight. While we value the contributions each of our directors brings to the table. It's important to rightsize the board given the changes of cost reductions being implemented at the corporate level board members, John Andrews, Michael Garrity and Craig Swanell have stepped down from the board effective this week. John, Michael and Craig each have served on apex board with dedication for many years and their steady leadership and port for council have helped advance Apyx mission to be a leader in the cosmetic surgery market in line with the same thought process and in order to be fully aligned with shareholders, the board has also decided to take a significant reduction in cash compensation. The board has added John Featherstone as a board observer to further bolster our commercial efforts and align our interests more closely with shareholders. John is an accomplished commercial executive with over 20 years of progressive leadership experience in the aesthetic and medical devices. He has held senior leadership positions at several leading medical aesthetics companies including Cyrela Biosystems Inc, Qra Inc and Sinosure Inc, where he led strategic initiatives that drove revenue and built high performance teams. We are pleased to announce our lender and partner perceptive advisors has agreed to amend the revenue covenants as a result of the near term macro challenges which caused us to narrowly miss the covenant this quarter. We've also added a covenant on total operating expenses in 2025 and 2026 which is in line with our plans. We are pleased to announce a $7 million registered direct cash investment from Manta Harlan Capital Management which serves to strengthen our balance sheet and further validates the potential of our technology. As a significant shareholder who purchased over 1.7 million shares in the spring due to my belief in the technology and its ability to provide superior results for doctors and patients. I remain optimistic that the team will return the company to growth I wanted to be clear that the Apyx management team has the board's complete confidence and support. I've worked closely with Charlie and Matt over the last few months and I'm positive that we have the right team in place. We view this restructuring as a necessary step to extend our runway and return to growth. I'll now turn the call over to Charlie to provide the third quarter update, Charlie.
謝謝 Charlie 邀請我參與今天的電話會議,說明 Apyx 正在進行的策略性變更,以及我們所採取、我們相信可強化公司資產負債表的財務行動。首先,如同今日稍早發布的新聞稿所宣布,Apyx 董事會與管理團隊已決定推動組織重整,預期可更聚焦公司資源並精簡營運。在本次重整下,Apyx 將其美國員工人數削減近 25%。作為裁減的一部分,銷售與行銷執行副總裁 Todd Hornsby 將即刻離職。Todd 十多年來一直是我們銷售團隊的重要成員。我們感謝他在此期間對公司的貢獻。在新的架構下,Charlie 除了其執行長的其他職責外,也已直接承擔銷售組織的責任;提醒各位,Charlie 擁有數十年領導醫療器材銷售團隊的經驗,具備良好條件來支持該職能,以便釋放 Charlie 的時間。我也很高興宣布,Sean Roman 已由其現任研發副總裁升任營運長(COO);Sean 自 2015 年起即在公司任職,十分勝任其新職務,稍後將進一步說明。Matt 將說明預期的成本削減與一次性費用的細節,以及本次重整預期如何將我們的資金可支撐期延長至 2027 年。我想清楚說明,這並非董事會或管理層輕率做出的決定。我們審慎評估各種選項後,認定為了未來、配合我們具顛覆性的全新平台推出,有必要透過本次重整使業務規模更為適當;該平台將使公司能以多項同級最佳解決方案在外科醫美領域取得主導地位。我們預期將看到我們「movie on」技術的使用率進一步提升,並帶動整體重回成長。Charlie 將在稍後進一步闡述這個令人振奮的新平台。接著談到正在推動的董事會變更。我們已決定調整董事會規模,將席次由目前的 8 席減至 5 席董事。我們重視每位董事所帶來的貢獻。然而,鑑於公司層級正在推動的成本削減措施,調整董事會規模十分重要;董事 John Andrews、Michael Garrity 與 Craig Swanell 已於本週起辭任董事職務。John、Michael 與 Craig 多年來以高度投入服務於 Apyx 董事會;他們穩健的領導與支持及建言,協助推進 Apyx 成為美容外科市場領導者的使命。基於相同思維,並為與股東充分一致,董事會也決定大幅降低現金報酬。董事會另增聘 John Featherstone 擔任董事會觀察員,以進一步強化我們的商業推進,並使我們的利益與股東更緊密一致。John 是一位傑出的商業主管,在醫美與醫療器材領域擁有超過 20 年循序晉升的領導經驗。他曾在多家領先的醫療美學公司擔任資深領導職務,包括 Cyrela Biosystems Inc、Qra Inc 與 Sinosure Inc;在這些公司中,他主導推動帶動營收的策略性計畫並建立高績效團隊。我們也很高興宣布,我們的放款人與合作夥伴 Perceptive Advisors 已同意修訂營收契約條款(revenue covenants),原因是短期宏觀環境挑戰導致我們本季些微未達該契約要求。我們亦在 2025 年與 2026 年新增一項關於總營運費用的契約條款,與我們的計畫一致。我們很高興宣布,Manta Harlan Capital Management 提供 700 萬美元的註冊直接現金投資(registered direct cash investment),此舉可強化我們的資產負債表,並進一步驗證我們技術的潛力。作為一名重要股東,我在春季因相信該技術及其為醫師與病患帶來更優異成果的能力而買入超過 170 萬股。我仍對團隊能讓公司重回成長抱持樂觀;我也想明確表示,Apyx 管理團隊獲得董事會完全的信任與支持。過去幾個月我與 Charlie 與 Matt 密切合作,我確信我們已具備合適的團隊。我們將本次重整視為延長資金可支撐期並重回成長的必要一步。現在我把電話交回給 Charlie,請他提供第三季更新。Charlie。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Thank you Stavros, the management team and I appreciate your support. The board's decision to make its own set of cost reductions alongside the corporate restructuring, speaks volumes and is a positive signal to the entire team that everyone is committed to bring down costs while utilizing our resources to drive future revenue growth. Moving now to our review of our third quarter performance, we reported total revenue of 11.5 million for the quarter a decrease of 4% compared to 12 million for the same period last year. Looking at this by segment sales of our advanced energy products decreased 6% year over year to 9.3 million. Our year over year business was down due to soft generator capital sales. This is not unique to us and have seen other companies in the aesthetic space experiencing the same challenges due to the macroeconomic environment and GLP One drugs which has affected procedural volume. What I am excited to share with you is that in spite of the reduction in the number of surgical procedures in our space in the third quarter, our disposable handpiece revenue grew 9% overall and 15% in the United States. This year, we are approaching 90,000 units globally and disposable revenue now accounts for more than 60% of our total AE revenue. Our OEM or generator manufacturing business continues to perform well and grow. Going forward we see even more opportunities for our technology due to the rapid uptake in the GLP one drugs and their associated side effects of loose skin. The broader market pressures I referred to are tied to the emergence of GLP One drugs which has resulted in patients postponing aesthetic procedures. We expect these macroeconomic challenges will continue to negatively impact the capital equipment side of our business through the near future. While this market shift has pressured sales of our generators. Over the past year to 18 months, we believe there is an emerging opportunity within the market for surgical treatment of loose skin and our team is moving quickly to position Apyx to be the leader due to this rapid weight loss, these patients will suffer significant loose and lax skin which will require a surgical intervention and or body contouring procedure which provides a durable and transformational result as compared to non-invasive procedures, considering the size of the population already on GLP One drugs over time, this has the potential to be a significant tailwind for reunion which is the only FDA approved solution for loose skin. We believe this should be the standard of care for these patients. We are approaching 400,000 procedures performed using renuvion. The procedure has proven to be transformational and durable for patients. Part of our strategy is to educate patients and doctors on the benefits of using renuvion to treat loose and lax skin. We have launched a direct to consumer strategy in order to generate broader awareness for renuvion at the patient level. This program leverages key influencers amplifying awareness through our premier lifestyle expos and exclusive retreats that boost visibility for renuvion. In addition, we have launched a campaign to educate patients and physicians on Renuvion as the number one trusted contouring technology focused on loose skin and approximately 50% of consumers say they would consider a treatment to reduce loose skin because they want to look and feel more like themselves in order to enhance patient outcomes and continue to lead surgical aesthetics. We are excited to announce the Apyx team is in the final stages of developing the Aon body contouring system. Aon is an all in one platform that seamlessly integrates renuvion, ultrasound assisted liposuction, power assisted liposuction, infiltration, aspiration, electrocoagulation, and fat transfer into a single streamlined device. We believe Aon is a game changer for surgeons that will differentiate us and position Apyx as their surgical partner. I can picture a time when we walk into just about any surgeon's practice and see an Aon positioned in the heart of their operating room. Our goal is to be the company that surgeons think of when it comes to all of their surgical needs. We currently plan to submit a 510(k) for Aon to the FDA no later than the end of Q1 2025 which we believe would put us on track to launch this new system in the second half of 2025 which should kick start equipment sales growth again as we have the opportunity to capture new market share and expand our total addressable market in aesthetic surgery. This is an exciting opportunity for our business that is in the early stages. We look forward to gaining traction as we close out 24 and into 2025. I will now turn the call over to Matt for a review of our third quarter financial results in more detail along with our financial guidance for 24 which we updated in today's release.
謝謝你,Stavros;管理團隊和我都感謝你的支持。董事會決定在公司重整的同時,自行推動一套成本削減措施,這充分說明了一切,並向整個團隊釋放出正面訊號:每個人都致力於在善用資源以推動未來營收成長的同時,降低成本。接著回顧我們第三季的表現:本季我們的總營收為1,150萬美元,較去年同期的1,200萬美元下降4%。按部門來看,我們先進能源(AE)產品的銷售額年減6%至930萬美元。我們的年對年業務下滑,主要是因為發電機資本設備銷售疲弱。這並非我們獨有;我們也看到美學醫療領域的其他公司因總體經濟環境以及GLP-1藥物而面臨相同挑戰,後者已影響手術量。我很高興與各位分享的是:儘管第三季我們所處領域的手術數量下降,我們的一次性手柄(disposable handpiece)營收整體仍成長9%,在美國更成長15%。今年我們全球出貨量正接近90,000支,而一次性耗材營收目前已占我們AE總營收的60%以上。我們的OEM(原廠委託製造)或發電機製造業務持續表現良好並成長。展望未來,隨著GLP-1藥物快速普及及其相關的皮膚鬆弛副作用,我們看到技術將有更多機會。我先前提到的更廣泛市場壓力,與GLP-1藥物的興起有關,這使得患者延後進行醫美療程。我們預期這些總體經濟挑戰在可預見的未來仍將持續對我們業務中的資本設備端造成負面影響。雖然這一市場轉變已對我們發電機的銷售造成壓力。在過去12至18個月,我們認為市場上正浮現一個針對皮膚鬆弛的手術治療機會;我們的團隊正迅速行動,將Apyx定位為領導者。由於快速減重,這些患者將出現明顯的皮膚鬆弛與彈性不足,將需要手術介入及/或體雕療程;相較於非侵入式療程,這些方式能提供更持久且具轉變性的效果。考量到目前已有大量人口正在使用GLP-1藥物,隨時間推進,這有潛力成為Renuvion的重要順風因素;Renuvion是唯一獲FDA核准用於皮膚鬆弛的解決方案。我們相信這應成為這些患者的標準照護。我們正接近使用Renuvion完成的400,000例療程。該療程已被證明能為患者帶來具轉變性且持久的效果。我們策略的一部分,是教育患者與醫師使用Renuvion治療皮膚鬆弛與彈性不足的益處。我們已推出直接面向消費者(DTC)的策略,以在患者層面為Renuvion建立更廣泛的認知。此計畫運用關鍵意見領袖,並透過我們的頂級生活風格博覽會與專屬靜修活動放大聲量,提升Renuvion的能見度。此外,我們也啟動一項宣傳活動,向患者與醫師教育:Renuvion是最受信賴、以皮膚鬆弛為核心的第一大體雕技術;約有50%的消費者表示,他們會考慮接受減少皮膚鬆弛的治療,因為他們希望看起來與感覺更像自己,以提升患者治療成效並持續引領外科醫美領域。我們很高興宣布,Apyx團隊正處於開發Aon體雕系統的最後階段。Aon是一個一體化平台,可將Renuvion、超音波輔助抽脂、動力輔助抽脂、注入、抽吸(aspiration)、電凝(electrocoagulation)以及脂肪移植無縫整合至單一精簡設備中。我們相信Aon將為外科醫師帶來顛覆性改變,能使我們脫穎而出,並將Apyx定位為他們的外科合作夥伴。我可以想像,未來我們走進幾乎任何外科醫師的診所,都能看到一台Aon擺放在手術室的核心位置。我們的目標是成為外科醫師在所有手術需求上首先想到的公司。我們目前計畫最遲於2025年第一季末向FDA提交Aon的510(k)申請;我們相信這將使我們有望在2025年下半年推出這套新系統,並再次帶動設備銷售成長,因為我們有機會取得新的市占並擴大我們在醫美外科的整體可服務市場(TAM)。這對我們仍處於早期階段的業務而言,是一個令人振奮的機會。我們期待在2024年收官之際並邁入2025年時取得進展。接下來我將把電話交給Matt,請他更詳細回顧我們第三季的財務結果,以及我們在今日公告中更新的2024年財務指引。
Matt Hill - Chief Financial Officer
Matt Hill - Chief Financial Officer
Thanks Charlie before I get started, please note that all references to third quarter financial results will be on a GAAP in year over year basis unless noted otherwise, as Charlie mentioned, we reported a 4% decrease in total revenue to $11.5 million in the third quarter of 2024 when compared with the $12 million for the third quarter of 2023. This was primarily due to advance energy revenue which decreased 6% year over year to $9.3 million. The advanced energy decrease is mostly driven by a lower average selling price of advanced energy generators to domestic customers, fewer domestic customer upgrades to the Apyx one console and a decrease in international sales of new generators. These decreases were partially offset by increased volume of single use handpieces domestically and sales of upgrades to the Apyx one console internationally. OEM segment sales increased 3% approximately $0.1 million in the third quarter of 24 when compared to the third quarter of 23 the increase in OEM sales was due to increases in sales volumes to existing customers. Gross profit for the third quarter of 24 decreased $1 million or 13% to $7 million. Gross profit margin was 60.5% compared to 66.6% in the prior year period. The decrease in our gross margin was primarily driven by a decrease in the average selling price of generators changes in the sales mix between our two segments with our OEM segment comprising a higher percentage of total sales and changes in geographic mix within our advanced energy segment with international sales comprising a higher percentage of total sales. Operating expenses decreased $2 million or 16% to $10.6 million reflecting our continued emphasis on controlling costs including the elimination of 24 bonuses. The decrease in operating expenses was primarily driven by salaries and related costs and selling and general administrative expenses which decreased by $1 million and $0.6 million respectively. Loss from operations decreased $1 million or 22% to $3.6 million, total other expense net was $1 million compared to $0.4 million in the third quarter of 23 the change was driven primarily by increased net interest expense related to our outstanding debt obligations in the third quarter of 24 as we had lower borrowings in the prior year period. Net loss attributed to shareholders was $4.7 million or 14¢ per share compared to $4.6 million or 13¢ per share in the prior year period. Adjusted EBITDA loss decrease $0.6 million or 20% to $2.4 million compared to $3.1 million in the third quarter of 23. As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted even a loss in our earnings press release. For the three months ended, September 30 2024 cash used from operating activities was $4.4 million which is consistent with $4.4 million used in the prior year period after adjusting for a one time tax refund of $8.1 million. As of 30 September 24 the company had cash and cash equivalents of $28 million compared to $43.7 million as of 31 December 23 we're pleased to announce we have closed $7 million registered direct offering but not to have a capital management allowing us to strengthen our balance sheet. In addition, we amended our credit agreement with our lender and partner perceptive advisors, reducing our revenue covenants and adding max operating expense covenants at $40 & $45 million for 25 and 26 respectively. Associated with the amendment we issued to perceptive 150,000 shares of our common stock. As Stavros discussed in his prepared comments, we've just implemented a cost savings restructuring that will reduce our workforce by nearly 25%. We estimate the annualized future cost savings from the reduction in force to be approximately $4.3 million which we expect to contribute to our goal of decreasing loss and achieving cash flow break even. We will incur pre-tax charges of approximately $0.6 million in the fourth quarter of 24 representing for the most part one time cash expenditures, severance and other employee termination benefits. In addition to the organizational changes, we have identified other direct cost savings we anticipate achieving in 2025 the identified cost savings which include among other initiatives, the reduction in professional fees, the research and development costs. As we complete the development of Aon credit card fees and stock compensation, we foresee in totality these cost savings will reduce our operating expenses below $40 million. Turning to a review of our 24 guidance which we updated in our earnings press release today for the 12 months ending 31 December 24 we expect total revenue in the range of $46.6 million to $47.6 million representing a decrease of approximately 11% to 9% year over year. Our revenue guidance assumes advanced energy revenue in the range of $37.2 million to $38.2 million representing a decrease of approximately 14% to 12% year over year. OEM revenue is expected to come in at approximately $9.4 million representing growth of 5%. This range assumes approximately $2 million OEM revenue in the fourth quarter of 24.
謝謝你,Charlie。在我開始之前,請注意,除非另有說明,所有對第三季財務結果的引用皆以 GAAP 且以年對年基礎呈現。如 Charlie 所提到的,與 2023 年第三季的 1,200 萬美元相比,我們在 2024 年第三季的總營收下降 4% 至 1,150 萬美元。這主要是因先進能源(Advanced Energy)營收年對年下降 6% 至 930 萬美元所致。先進能源的下滑主要由以下因素驅動:對國內客戶的先進能源發電機平均售價較低、國內客戶升級至 Apyx One 主機(console)的數量較少,以及國際新發電機銷售下降。上述下滑部分被國內一次性手把(single use handpieces)銷量增加,以及國際市場 Apyx One 主機升級銷售所抵銷。OEM 事業部門銷售在 2024 年第三季較 2023 年第三季增加 3%,約增加 0.1 百萬美元;OEM 銷售增加係因對既有客戶的銷售量提升。2024 年第三季毛利下降 100 萬美元或 13% 至 700 萬美元。毛利率為 60.5%,相較於去年同期的 66.6%。毛利率下降主要由以下因素造成:發電機平均售價下降、兩個事業部門之間的銷售組合變化(OEM 事業部門占總銷售比重提高),以及先進能源事業部門內的地理組合變化(國際銷售占總銷售比重提高)。營業費用下降 200 萬美元或 16% 至 1,060 萬美元,反映我們持續強調成本控管,包括取消 2024 年獎金。營業費用下降主要來自薪資及相關成本,以及銷售與一般及行政費用,分別下降 100 萬美元與 60 萬美元。營業損失下降 100 萬美元或 22% 至 360 萬美元;其他費用淨額為 100 萬美元,相較於 2023 年第三季的 40 萬美元。變動主要由 2024 年第三季與我們未償債務義務相關的淨利息費用增加所致,因去年同期借款較少。歸屬於股東的淨損為 470 萬美元或每股 14 美分,相較於去年同期的 460 萬美元或每股 13 美分。調整後 EBITDA 損失減少 60 萬美元或 20% 至 240 萬美元,相較於 2023 年第三季的 310 萬美元。提醒一下,我們在盈餘新聞稿中提供從歸屬於股東的淨損到非 GAAP 調整後 EBITDA 損失的詳細調節表。截至 2024 年 9 月 30 日止三個月,營運活動使用現金為 440 萬美元;在調整 810 萬美元一次性退稅後,與去年同期使用的 440 萬美元一致。截至 2024 年 9 月 30 日,公司持有現金及約當現金 2,800 萬美元,相較於 2023 年 12 月 31 日的 4,370 萬美元。我們很高興宣布已完成 700 萬美元的註冊直接發行(registered direct offering),並進行資本管理,使我們得以強化資產負債表。此外,我們與貸方及合作夥伴 Perceptive Advisors 修訂了信貸協議,降低營收契約條款(revenue covenants),並新增最高營業費用契約條款(max operating expense covenants),2025 年與 2026 年分別為 4,000 萬美元與 4,500 萬美元。配合該修訂,我們向 Perceptive 發行 150,000 股普通股。如 Stavros 在其預先準備的評論中所述,我們剛實施一項節省成本的重整措施,將使員工人數減少近 25%。我們估計此次裁員帶來的未來年度化成本節省約為 430 萬美元,預期將有助於我們降低虧損並達成營運現金流量損益兩平的目標。我們將在 2024 年第四季認列約 60 萬美元的稅前費用,主要為一次性現金支出,包括資遣費及其他員工終止福利。除組織調整外,我們也已辨識出其他可望於 2025 年達成的直接成本節省;已辨識的節省項目包括(但不限於)降低專業服務費與研發成本等措施。隨著我們完成 Aon 的開發、降低信用卡手續費與股票薪酬,我們預期整體而言,這些成本節省將使我們的營業費用降至 4,000 萬美元以下。接著回顧我們對 2024 年的指引(我們已於今日的盈餘新聞稿中更新):截至 2024 年 12 月 31 日止 12 個月,我們預期總營收介於 4,660 萬至 4,760 萬美元,年對年約下降 11% 至 9%。我們的營收指引假設先進能源營收介於 3,720 萬至 3,820 萬美元,年對年約下降 14% 至 12%。OEM 營收預期約為 940 萬美元,代表成長 5%。此區間假設 2024 年第四季 OEM 營收約為 200 萬美元。
In terms of our profitability guidance for fiscal year '24 we expect a net loss attributable to stockholders of approximately $25 million compared to our prior expectation of approximately $24.5 million to $23.5 million. The low end of our formal financial guidance for net loss, tribal stockholders now assumes the following for modelling purposes. First, gross margins of approximately 60% this year. Second, we expect total operating expenses in the range of 48 to $49 million. Lastly, at the low end of our net loss, we expect cash used in operations in 24 of approximately $20.1 million. This compares to cash normalized cash used in operations of approximately $13 million in 23 excluding the onetime tax benefit in the third quarter of 2023 year over year, change in cash used in operations is driven by the change in net loss offset by improvements in working capital.
就 2024 會計年度的獲利能力指引而言,我們預期歸屬於股東的淨損約為 2,500 萬美元,相較於先前預期約 2,450 萬至 2,350 萬美元。我們正式財務指引中淨損的低端(歸屬於股東)目前為建模目的假設如下:第一,今年毛利率約為 60%。第二,我們預期總營業費用介於 4,800 萬至 4,900 萬美元。最後,在淨損低端情境下,我們預期 2024 年營運活動使用現金約為 2,010 萬美元。相較之下,2023 年在排除 2023 年第三季一次性稅務利益後,常態化的營運活動使用現金約為 1,300 萬美元。年對年營運活動使用現金的變動係由淨損變動所驅動,並部分被營運資金改善所抵銷。
Lastly, in our earnings release today, we introduced 2025 revenue guidance for the 12 months ending 31 December 25. We expect total revenue in the range of $47.6 million to $49.5 million representing a growth of approximately 2% to 6% year over year when compared to the low end of our 24 guidance range, our total revenue guidance range assumes advanced energy revenue in the range of $39.1 million to $41 million representing a growth of approximately 5% to 7% year over year. OEM revenue is estimated approximately $8.5 million representing a decrease of approximately 10% year over year as we return to more normalized customer ordering and order fulfilment. We expect that these revenue results will be achieved with operating expenses of no greater than $40 million. We believe based on our projections including the uptake of the Aon platform, working capital management, our strict cost controls and the recent capital investment wheel of cash into 2027. This completes our prepared remarks, Charlie and I will now open the call for questions, operator.
最後,在我們今天發布的財報新聞稿中,我們提出了截至2025年12月31日止12個月的2025年營收指引。我們預期總營收將介於4,760萬美元至4,950萬美元之間;相較於我們2024年指引區間低端,約為年增2%至6%。我們的總營收指引區間假設先進能源(Advanced Energy)營收介於3,910萬美元至4,100萬美元之間,約為年增5%至7%。OEM營收估計約為850萬美元,隨著我們回到較為正常化的客戶下單與訂單履行節奏,約為年減10%。我們預期在營業費用不超過4,000萬美元的情況下達成上述營收結果。我們相信,根據我們的預測(包括Aon平台的採用進展、營運資金管理、嚴格的成本控制,以及近期的資本投資),現金可支應至2027年。以上為我們事先準備的發言內容。Charlie和我現在將開放提問,接線員。
Operator
Operator
Thank you. Ladies and gentlemen, we will now be conducting a question and answer session. If you'd like to ask a question, please press star and one on your telephone keypad. Our confirmation tone will indicate your line is in the question queue. You may press star and two if you'd like to remove your question from the queue for participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.
謝謝。各位女士先生,我們現在將進行問答環節。若您想提問,請在電話鍵盤上按星號再按1。確認提示音將表示您的線路已進入提問佇列。若您想將問題自佇列中移除,請按星號再按2。對於使用擴音設備的與會者,可能需要先拿起話筒再按星號鍵。
Ladies and gentlemen, we will wait for a moment while we poll for questions.
各位女士先生,我們將稍候片刻以收集問題。
The first question comes from the line of Matthew O'brien from Piper Sandler. Please go ahead.
第一個問題來自Piper Sandler的Matthew O'brien。請開始。
Matthew O'brien - Analyst
Matthew O'brien - Analyst
Great. Thanks for taking the questions and Stavros good to reconnect here a bit this morning. Maybe just starting with 25 in the Advanced Energy Commentary earlier or Matt just where is this growth is, you know, kind of 7.5% going to come from? Is it really just on the hand piece side of things or do you expect the generator side to start to flatten out and even improve somewhat next year as rates start to fall a bit?
很好。謝謝讓我提問,Stavros,很高興今天早上能再跟你連線聊一下。也許先從先進能源(Advanced Energy)對2025年的評論開始,或Matt剛剛提到的部分:這個大約7.5%的成長,你們認為會來自哪裡?是否真的主要來自手持器(hand piece)端?還是你們預期隨著利率開始下降,發電機(generator)端明年會趨於持平,甚至有所改善?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah. So thanks for the question, Matt. Our budget for 25 assumes that the capital equipment market stays the same that it is right now to your point. It is not expected to do that, it is expected to get better, but from a budget perspective, that is our that that is our expectation that it doesn't get any better and it stays exactly the way that it is now and so yes, that growth would come from hand, continued hand piece growth and a little bit from Aon in the back half.
是的。謝謝你的問題,Matt。我們對2025年的預算假設資本設備市場維持目前的狀況,正如你所說。我們並不預期它會一直如此;我們預期會變好,但就預算角度而言,我們的假設是它不會變得更好,而是完全維持現在的樣子。因此,是的,那個成長將來自手持器的持續成長,以及下半年Aon帶來的一點貢獻。
Matthew O'brien - Analyst
Matthew O'brien - Analyst
Got it and then can you just talk a little bit more about Aon, you know, and, and coming to market with such a robust product. First of all, just the development requirements to get that product to market. I mean, 510(k) seems like it makes sense, although something as robust as this seems pretty differentiated. So I'm not sure what you anchor it to specifically but just you know how that that product specifically can catalyze the company late next year and then ended 26.
了解。那你能否再多談一點Aon?你知道,以這麼強大的產品推向市場。首先,為了讓該產品上市,開發需求是什麼?我的意思是,510(k)看起來合理,雖然像這麼完整的產品似乎相當差異化。所以我不確定你們具體是以什麼作為對照基準;但想請你談談,這個產品本身如何在明年下半年催化公司成長,並延續到2026年底。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Thanks. Yeah, thanks for the question and I'm, I'm so happy that we actually get to actually talk about this now because it's been in the development for quite a while and it's been part of our overall strategy to be the company that all aesthetic surgeons think about for surgery we think that this is a game changer we think combined with the apex one generator that this becomes the heart and soul of every doctor's operating room because quite frankly, there's not a single surgical procedure that they cannot do without this platform now and it's all integrated into one incredibly nice package, but it is just a 510(k) and I don't want to say anything is relatively simple, but there are predicate devices for all the technologies and so that makes it a lot easier when you're going through the 510(k) route and we actually did a pre submission already with the FDA to let them know what is coming and already got their feedback. So we feel pretty good that we're on the right path for getting this through the agency in a pretty good length of time but obviously, it's, it's incredibly exciting for us here at Apyx Medical and something that you know, it's been the hardest thing not to talk about for the longest time now. So because we've been working on it for a while, obviously.
謝謝。是的,謝謝你的問題。我很高興我們終於可以談這件事,因為它已經開發了相當長一段時間,也是我們整體策略的一部分:成為所有醫美外科醫師在手術時會想到的公司。我們認為這是一個改變遊戲規則的產品;我們認為它與Apex One發電機結合後,將成為每位醫師手術室的核心與靈魂,因為坦白說,現在沒有任何一項外科手術程序是他們在沒有這個平台的情況下無法進行的;而且它全部整合在一個非常出色的套裝中。不過它確實只是走510(k)途徑;我不想說任何事情「相對簡單」,但針對所有技術都有可作為前例(predicate)的器材,因此走510(k)路徑時會容易許多。我們也已經先向FDA做過pre-submission,讓他們知道即將送件的內容,並且已收到他們的回饋。因此我們對於能在相當合理的時間內通過主管機關審查,感覺相當有把握;但顯然,這對我們Apyx Medical而言非常令人振奮,也是你知道的,長時間以來最難忍住不談的事情。因為我們已經為此努力了一段時間,顯然如此。
Matt Hill - Chief Financial Officer
Matt Hill - Chief Financial Officer
Got it. Thank you.
了解。謝謝你。
Operator
Operator
Thank you. The next question comes from the line of Matt Hewitt from Craig Hallum Capital Group. Please go ahead.
謝謝。下一個問題來自Craig Hallum Capital Group的Matt Hewitt。請開始。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Good morning thank you for taking the questions. So maybe first up, can we talk a little bit about the environment right now? I obviously with expectations that rates are going to come down. How are you positioning for this return to growth in 2025? Either from a pricing perspective or, you know, are you still actively participating in marketing campaigns? Just what, how do you kind of position things for growth next year?
早安,謝謝讓我提問。那也許先談談目前的環境?顯然市場預期利率會下降。你們如何為2025年重回成長做準備?不論是從定價角度,或是你知道的,你們是否仍在積極參與行銷活動?總之,你們大概如何為明年的成長做布局?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah. No, it's a great question as you know, we talked about on the call, we unfortunately had a 25% reduction in our force this week to lower our cost basis and to basically right size the organization and get us ready for all of this but one of the things that we actually are spending more on next year is our direct to consumer campaign. It is we're starting to see unbelievable metrics from that the uptick is starting to be really good from the efforts that we're putting in there and we think that you know, putting more on that and educating patients more about the options that they have for loose skin is going to pay dividends and as I've mentioned before, it's not just direct to consumer, it is also business to business too and so that is an area of focus for us as we move into 25 and into 26 to help do this and so that is, that is something that we will keep doing.
是的。這是個很好的問題。如同你知道的,我們在電話會議中提到,很不幸地,我們本週將人力縮減了25%,以降低成本基礎,基本上是讓組織規模更貼近需求,並為接下來的一切做好準備。不過,我們明年實際上會增加投入的一個項目,是我們的直接面向消費者(direct to consumer)活動。我們開始看到非常驚人的指標表現;我們在那方面投入的努力正帶來很好的上升動能。我們認為,增加這方面的投入、並讓病患更了解他們針對皮膚鬆弛所擁有的選項,將會帶來回報。正如我之前提過的,這不只是直接面向消費者,也包含企業對企業(business to business)。因此,當我們邁入2025年與2026年時,這將是我們的重點領域之一,以協助推動成長;所以這是我們會持續做的事情。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Got it and then regarding the Aon, just a couple of things first, it's exciting to hear that you're launching this new product, will this replace Renuvion? Is it the same generator? And then just different attachments? I'm just trying to figure out if there's any risk to maybe cannibalizing a little bit of the Renuvion market. Just help me understand that a little bit better.
了解,那接著關於 Aon,我先問幾點:很令人振奮聽到你們要推出這個新產品,它會取代 Renuvion 嗎?是同一台產生器嗎?然後只是不同的附件?我只是想弄清楚,是否可能會有一點點侵蝕 Renuvion 市場的風險。請幫我更好地理解一下。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah. No, it's a good, it's a really good question and it's really important at this point that everybody understands the heart and soul of the Aon system the brains of the Aon system is the Apyx one generator. The Apyx one generator was designed with this in mind because obviously we had this in the works too and so the Aon system will not work without an Apyx one and so for all the doctors that have already upgraded to the Apyx one now, they could just upgrade the rest of their body contouring offering around that and for the doctors who have the RS3, they would need to upgrade to apex first for that because the Apyx one is the key and for all the other technologies that are in Aon, I think it's important to note this. When we looked at designing this system, we worked with some of the top body contouring doctors in the world to help design this platform and we have taken everything that is in there and made it better and state of the art, some of these technologies that are that are in Aon had not been enhanced in about 20 years and you can imagine with technology 20 years is is is antiquated and so we have not only taken some of the technologies and made them better, but we have taken all of the process and all of the things that help make the procedure safer faster, more convenient for the doctor and then we have put it elegantly into one tower and So if you think about space in these procedure rooms, they've got stuff all over the place this is going to be elegant and all into one tower with state of the art, everything that exists in the marketplace today.
是的。不,這是個好問題,真的非常好的問題,而且在這個時間點讓每個人都理解很重要:Aon 系統的核心與靈魂、Aon 系統的大腦,就是 Apyx One 產生器。Apyx One 產生器在設計時就把這點納入考量,因為很顯然我們也在同步開發,所以 Aon 系統沒有 Apyx One 就無法運作。因此,所有已經升級到 Apyx One 的醫師,現在只需要在此基礎上把其餘的體雕產品組合升級即可;而對於使用 RS3 的醫師,則需要先升級到 Apyx One,因為 Apyx One 是關鍵。至於 Aon 中的其他技術,我認為這點很重要:當我們著手設計這套系統時,我們與全球一些頂尖的體雕醫師合作來協助設計這個平台;我們把裡面的每一項都做得更好、更先進。Aon 中有些技術大約 20 年都沒有被強化過,你可以想像在科技領域,20 年就已經非常老舊了。因此,我們不僅把部分技術做得更好,也把所有流程與所有能讓手術更安全、更快速、對醫師更便利的要素都整合起來,並且優雅地放進一座塔式主機中。所以如果你想到這些手術室的空間,設備常常到處都是;這套會很精緻,全部整合在一座塔式主機裡,並配備目前市場上最先進的一切。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
That that's super helpful. Thank you, Charlie.
這非常有幫助。謝謝你,Charlie。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Thank you.
謝謝。
Operator
Operator
Thank you. The next question is from the line of Sam Eiber from BTIG. Please go ahead.
謝謝。下一個問題來自 BTIG 的 Sam Eiber。請繼續。
Sam Eiber - Analyst
Sam Eiber - Analyst
Hey, good morning, everyone. Thanks for taking the questions this morning. Maybe I can start on the reduction in force and just better understand where some of the reductions are coming from. Is it really across the board? Are you still maybe emphasizing some of the commercial teams? Just one on, better understand where where that's coming from?
嗨,各位早安。謝謝今天早上回答問題。我想先從裁員(reduction in force)談起,想更清楚了解部分裁減是從哪些地方來的。這真的是全面性的嗎?你們是否仍然可能更著重某些商業團隊?想更好理解這是從哪裡來的?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah, it was really across the board of the or the entire organization we looked at things that we could live without and focus on the things that we had to have over the next couple of years to get the profitability and I just want to be clear on that 25% that was just in the US, the Bulgaria facility stays the same, but that was just a US reduction.
是的,基本上是橫跨整個組織、整個公司。我們檢視了哪些是我們可以不需要的,並把重點放在未來幾年為了達成獲利所必須具備的事項。我也想釐清:那 25% 只是在美國,保加利亞的廠區維持不變;那只是美國的縮編。
Sam Eiber - Analyst
Sam Eiber - Analyst
Okay that's really helpful Charlie and then maybe following up on some of the questions for Aon and specifically the new features. You know, its this something surgeons are, are necessarily asking for, you know, updated ultrasound and pal also. Just want to better understand adding all those features and some of the benefits that could drive for for Apyx.
好的,這很有幫助,Charlie。接著也許延續一些關於 Aon 的問題,特別是新功能。你知道,這是外科醫師真的在要求的東西嗎,例如更新的超音波以及 PAL 等?只是想更好理解加入所有這些功能,對 Apyx 可能帶來哪些好處。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
The short answer to that is absolutely one of the things that they were asking for is to have all of this put together because they've got, you know, stuff all over their procedure room and space is limited, but we didn't want to just put it together. We wanted to make the procedure safer, faster, more efficient and everything else and so when you look at what we have actually done, we have actually made the surgeons and their staffs job easier in almost every way and this will help drive better patient outcomes. This will help drive more efficiency this will help reduce the time that is needed for the procedure and so there is really nothing that that this platform help these surgeons out and our goal obviously has always been to have renuvion be the standard of care for all of these body contouring procedures and we think this just tremendously helps in that area.
簡短的答案是:絕對是。其中一件他們一直在要求的,就是把這些全部整合在一起,因為他們的手術室裡到處都是設備,而空間有限;但我們不只是想把它們放在一起。我們想讓手術更安全、更快速、更有效率,以及其他各方面都更好。所以當你看我們實際做了什麼,我們幾乎在每個面向都讓外科醫師與其團隊的工作更容易,這將有助於帶來更好的病患結果。這將有助於提升效率、縮短手術所需時間。因此,這個平台確實能在各方面幫助這些外科醫師;而我們的目標顯然一直都是讓 Renuvion 成為所有這些體雕手術的照護標準(standard of care),我們認為這在這方面有極大的助益。
Operator
Operator
Thank you, the next question is from the line of Ben Haynor from Lake Street Capital Markets. Please go ahead.
謝謝。下一個問題來自 Lake Street Capital Markets 的 Ben Haynor。請繼續。
Ben Haynor - Anlayst
Ben Haynor - Anlayst
Good morning guys, thanks for taking the questions, first off for me on the $4 million in additional cost savings that you mentioned having been identified. How quickly, will those be put in place? And do you anticipate there are going to be any additional charges associated with those and then do the, any one time charges, do those count against the $40 million covenant?
各位早安,謝謝回答問題。首先我想問你們提到已識別出的額外 400 萬美元成本節省。這些會多快落地實施?你們預期會有任何與此相關的額外費用嗎?另外,任何一次性費用是否會計入 4,000 萬美元的契約(covenant)限制?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah. No, look, we've got everything there are no extra one time charges and just to give you a level of the cost reductions, the cost reductions just haven't been going on for 25 and 26 I think, I believe that we finished the end of last year with an operating expense of around 53 million. Matt's nodding his head, my CEO of math is correct and so we will go all the way from that over the next two years down to no more than 40 million next year and all of that has been factored into everything. So we've had substantial cost reductions this year too. We're just carrying it on to another level for next year.
是的。不,你看,我們都已經規劃好了,沒有額外的一次性費用。為了讓你了解成本削減的幅度,成本削減不只是發生在 25 年和 26 年;我想、我相信我們在去年底結束時的營運費用大約是 5,300 萬美元。Matt 正在點頭,我的 CEO——Matt——確認我說得沒錯;因此在接下來兩年,我們會從那個水準一路降到明年不超過 4,000 萬美元,而這些都已經納入所有規劃與假設中。所以我們今年也已經做了大幅的成本削減。我們只是把這件事在明年再推進到另一個層級。
Ben Haynor - Anlayst
Ben Haynor - Anlayst
So the that $4 million run rate that'll come out sometime in the current quarter and then you'll get the benefit of it as we get into 2025 and beyond.
所以,那每年約 400 萬美元的年化水準將會在本季的某個時間點反映出來,接著在我們進入 2025 年及之後,你們就會享受到其效益。
Matt Hill - Chief Financial Officer
Matt Hill - Chief Financial Officer
Yeah, that's correct so that the charges for that $0.6 million that we talked about is specifically related to Q4 in 24.
是的,沒錯;我們剛才提到的那 60 萬美元費用,明確是與 2024 年第四季相關。
Ben Haynor - Anlayst
Ben Haynor - Anlayst
Okay. Got it and then on the change in assumption on advanced energy utilization, how or did that change to inform the altered guidance for the remainder of the year. Is it mostly stay the same on the utilization side and and less on the capital side if that makes.
好的。了解,那麼關於先進能源使用率假設的變更,這項變更如何(或是否)影響了你們對今年剩餘期間的調整後指引?如果我這樣說得通的話,是否主要是使用率端大致不變,而資本端的影響較大?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah. No I understand the question. The utilization and the growth of our disposables is is still going to say, I think we said that we expect to grow disposables low double digits for the year and, and that still remains the same, the softness still is in the capital equipment market.
是的。不,我理解這個問題。使用率以及我們一次性耗材的成長仍會維持;我想我們說過,預期今年耗材將以低雙位數成長,而這點仍然不變;疲弱之處仍在資本設備市場。
Ben Haynor - Anlayst
Ben Haynor - Anlayst
Okay. Got it and then lastly, for me, it sounds like this a product is going to be quite the the unit but just curious if you, if you worry at all about kind of an Osborne effect where prospective customers kind of wait on things to, until, you know, this fantastic new unit comes out. I mean, do you think that that could impact capital sales as we get into, you know, I guess the remainder of this year in 2025?
好的。了解,最後一個問題:聽起來這個產品會是一台相當出色的設備,但我只是好奇你們是否會擔心所謂的 Osborne 效應,也就是潛在客戶可能會先觀望,等到這台很棒的新機型推出。我的意思是,你們認為這會在我們進入今年剩餘時間以及 2025 年時,影響資本設備銷售嗎?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
So, are you asking if it's going to hurt capital or potentially help capital?
所以,你是在問它會傷害資本銷售,還是可能有助於資本銷售?
Ben Haynor - Anlayst
Ben Haynor - Anlayst
Well, I would imagine by the end of the next year, it would certainly help but in the meantime, do you get folks that maybe would have purchased a unit kind of sitting on their hands waiting for Aon?
嗯,我想到了明年年底,它當然會有幫助;但在此期間,會不會有人原本會買一台設備,結果先按兵不動、等 Aon?
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Yeah, I think it's actually just the opposite because remember that doctors have to have the Apyx one in order to be able to use Aon and we will prioritize customers that already have the Apyx one to upgrade to Aon when it becomes available. So what, what we foresee happening is a lot of our doctors that would want a on could upgrade to the Apyx one, start using the Apyx one and continue using Renuvion and then when Aon comes out, we can upgrade the rest of the, of that system. So there is no reason that doctors would wait and in fact, it's just the opposite one of the reasons that we wanted to start talking about this too is because doctors are always planning, you know, their businesses and we've got people that are opening new practices and doing new things later in the year. We want to make sure that they know that this is an option for them and when they're looking to replicate the their body contouring, offering that that they would come and talk to us about that. So we don't see it as any hindrance in the short run in fact, it's probably a net net positive.
是的,我認為其實正好相反,因為請記得,醫師必須先擁有 Apyx one 才能使用 Aon,而當 Aon 可供時,我們會優先讓已經擁有 Apyx one 的客戶升級到 Aon。因此,我們預期會發生的是:許多想要 Aon 的醫師可以先升級到 Apyx one,開始使用 Apyx one 並持續使用 Renuvion;等 Aon 推出後,我們再把該系統其餘部分升級。所以醫師沒有理由等待;事實上正好相反。我們之所以也想開始談這件事,其中一個原因是醫師總是在規劃他們的業務,而且有人在今年稍晚開新診所、做新的安排。我們希望確保他們知道這對他們而言是一個選項,並且當他們想要複製其身體雕塑的服務內容時,他們會來找我們討論。所以我們不認為短期內會造成任何阻礙;事實上,整體而言可能是淨正面影響。
Ben Haynor - Anlayst
Ben Haynor - Anlayst
Okay Got it I just wanted to make sure, that's very helpful. Thanks for taking the questions.
好的,了解,我只是想確認一下,這非常有幫助。謝謝回答問題。
Operator
Operator
Thank you, ladies and gentlemen, this concludes our question and answer session. I would now hand the conference over to Charlie Goodwin for his closing comments.
謝謝各位女士先生,問答環節到此結束。我現在把電話會議交回給 Charlie Goodwin 作結語。
Charles D. Goodwin - President and Chief Executive Officer
Charles D. Goodwin - President and Chief Executive Officer
Thank everybody. Thank you, everybody for attending the call. We appreciate it very much and thanks for all your support. Thank you.
謝謝大家。謝謝各位參加本次電話會議。我們非常感謝,也謝謝各位的支持。謝謝。
Operator
Operator
Thank you. The conference of Apyx Medical has now concluded. Thank you for your participation. You may now disconnect your lines.
謝謝。Apyx Medical 的電話會議現在結束。感謝各位參與。您現在可以掛斷電話。